Development Of Pulmonary Dosage Forms For The Successful Delivery Of Complex Molecules

Pulmonary drug delivery is a well-established route for treating a wide range of respiratory diseases, from asthma and COPD to pulmonary hypertension and cystic fibrosis. Traditionally, metered dose inhalers (MDIs) and nebulisers have been used to deliver drugs throughout the respiratory tract; however, these devices often result in significant deposition in the throat and upper airways, reducing efficacy and increasing side effects.

As interest grows in delivering therapies deeper into the alveolar space — both for localized treatment and for systemic delivery — new challenges emerge. Many next-generation therapeutics are sensitive biologics or oligonucleotides that are unstable in aqueous formulations or incompatible with propellants used in MDIs. These limitations are driving the development of advanced delivery platforms, including soft mist inhalers (SMIs) and dry powder inhalers (DPIs), designed to enable efficient deep-lung deposition and improved stability of fragile molecules.

Discover how next-generation inhalation technologies can transform pulmonary drug delivery and unlock new therapeutic possibilities.